Kamada Stock Price, News & Analysis (NASDAQ:KMDA)

$5.30 +0.10 (+1.92 %)
(As of 02/22/2018 01:31 PM ET)
Previous Close$5.30
Today's Range$5.25 - $5.30
52-Week Range$3.75 - $8.61
Volume6,200 shs
Average Volume26,696 shs
Market Capitalization$209.37 million
P/E Ratio31.18
Dividend YieldN/A
Beta1.14

About Kamada (NASDAQ:KMDA)

Kamada logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Debt-to-Equity Ratio0.02%
Current Ratio3.30%
Quick Ratio2.58%

Price-To-Earnings

Trailing P/E Ratio31.1783046061533
Forward P/E Ratio25.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.82 million
Price / Sales2.08
Cash Flow$0.26 per share
Price / Cash20.12
Book Value$2.22 per share
Price / Book2.39

Profitability

Trailing EPS$0.17
Net Income$6.90 million
Net Margins6.71%
Return on Equity9.06%
Return on Assets6.46%

Miscellaneous

Employees377
Outstanding Shares40,260,000

Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd (NASDAQ:KMDA) released its earnings results on Wednesday, February, 7th. The biotechnology company reported $0.16 EPS for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.10. The biotechnology company earned $35.71 million during the quarter, compared to analysts' expectations of $32.90 million. Kamada had a return on equity of 9.06% and a net margin of 6.71%. View Kamada's Earnings History.

When will Kamada make its next earnings announcement?

Kamada is scheduled to release their next quarterly earnings announcement on Tuesday, May, 15th 2018. View Earnings Estimates for Kamada.

Where is Kamada's stock going? Where will Kamada's stock price be in 2018?

3 brokerages have issued 1 year price targets for Kamada's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Kamada's share price to reach $7.00 in the next year. View Analyst Ratings for Kamada.

Who are some of Kamada's key competitors?

Who are Kamada's key executives?

Kamada's management team includes the folowing people:

  • Leon Yehuda Recanati, Chairman of the Board (Age 67)
  • Amir London, Chief Executive Officer (Age 46)
  • David Tsur, Deputy Chairman of the Board (Age 67)
  • Chaime Orlev, Chief Financial Officer (Age 46)
  • Ruth Wolfson, Senior Vice President - Scientific Affairs (Age 69)
  • Barak Bashari, Vice President - Operations (Age 51)
  • Shani Dotan, Vice President - Human Resources (Age 42)
  • Yael Brenner, Vice President - Quality (Age 52)
  • Orit Pinchuk, Vice President - Regulatory Affairs and Quality R&D (Age 50)
  • Eran Schenker, Vice President - Medical Director (Age 53)

Who owns Kamada stock?

Kamada's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include MEITAV DASH INVESTMENTS LTD (9.17%), MEITAV DASH INVESTMENTS LTD (9.17%), Meitav Dash Investments Ltd. (1.84%) and ARK Investment Management LLC (0.13%). View Institutional Ownership Trends for Kamada.

Who bought Kamada stock? Who is buying Kamada stock?

Kamada's stock was bought by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd. and ARK Investment Management LLC. View Insider Buying and Selling for Kamada.

How do I buy Kamada stock?

Shares of Kamada can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of Kamada stock can currently be purchased for approximately $5.30.

How big of a company is Kamada?

Kamada has a market capitalization of $209.37 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.17 on an earnings per share basis. Kamada employs 377 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 7 SAPIR STREET KIRYAT WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7414002. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kamada (NASDAQ:KMDA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.00$8.50$8.50$8.50
Price Target Upside: 35.92% upside75.26% upside75.26% upside86.81% upside

Kamada (NASDAQ:KMDA) Consensus Price Target History

Price Target History for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018HC WainwrightReiterated RatingBuyHighView Rating Details
2/2/2018Chardan CapitalInitiated CoverageBuy -> Buy$7.00LowView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$7.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Kamada (NASDAQ:KMDA) Earnings History and Estimates Chart

Earnings by Quarter for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ KMDA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018        
2/7/2018n/a$0.06$0.16$32.90 million$35.71 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.01)$24.84 million$22.92 millionViewN/AView Earnings Details
8/1/20176/30/2017$0.12$0.13$33.30 million$32.55 millionViewListenView Earnings Details
5/16/20173/31/2017($0.03)($0.11)$20.82 million$11.65 millionViewN/AView Earnings Details
2/6/201712/31/2016($0.04)($0.05)$27.74 million$24.26 millionViewListenView Earnings Details
11/10/20169/30/2016($0.04)($0.03)$20.32 million$19.37 millionViewN/AView Earnings Details
8/2/2016Q216($0.04)($0.04)$18.50 million$19.10 millionViewN/AView Earnings Details
5/9/2016Q1 2016($0.06)($0.06)$15.10 million$14.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details
2/11/2015Q4$0.01$0.05$24.53 million$25.79 millionViewN/AView Earnings Details
11/12/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.01$0.03$16.30 million$16.12 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.03)($0.07)$12.60 millionViewN/AView Earnings Details
3/9/2013Q4 2012($0.03)$0.11ViewN/AView Earnings Details
2/28/2012Q4 2011($0.03)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Kamada (NASDAQ:KMDA) Earnings Estimates

2018 EPS Consensus Estimate: $0.22
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.02$0.02$0.02
Q2 20181$0.06$0.06$0.06
Q3 20181$0.05$0.05$0.05
Q4 20181$0.09$0.09$0.09
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Kamada (NASDAQ:KMDA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kamada (NASDAQ KMDA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Kamada (NASDAQ KMDA) News Headlines

Source:
DateHeadline
Kamada (KMDA) Upgraded at TheStreetKamada (KMDA) Upgraded at TheStreet
www.americanbankingnews.com - February 18 at 9:22 PM
Kamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 MillionKamada Ltd (KMDA) Expected to Post Quarterly Sales of $24.89 Million
www.americanbankingnews.com - February 15 at 4:32 AM
Zacks: Brokerages Anticipate Kamada Ltd (KMDA) to Post $0.03 Earnings Per ShareZacks: Brokerages Anticipate Kamada Ltd (KMDA) to Post $0.03 Earnings Per Share
www.americanbankingnews.com - February 13 at 11:14 AM
Jefferies Group Weighs in on Kamada Ltds Q1 2018 Earnings (KMDA)Jefferies Group Weighs in on Kamada Ltd's Q1 2018 Earnings (KMDA)
www.americanbankingnews.com - February 12 at 2:20 AM
Kamada (KMDA) Rating Increased to Hold at Zacks Investment ResearchKamada (KMDA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - February 11 at 9:36 AM
Research Analysts Offer Predictions for Kamada Ltds Q3 2018 Earnings (KMDA)Research Analysts Offer Predictions for Kamada Ltd's Q3 2018 Earnings (KMDA)
www.americanbankingnews.com - February 9 at 11:37 AM
Kamada (KMDA) Upgraded to "Hold" at ValuEngineKamada (KMDA) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 8 at 10:34 PM
Kamada (KMDA) Announces  Earnings ResultsKamada (KMDA) Announces Earnings Results
www.americanbankingnews.com - February 8 at 10:32 AM
Kamada posts 4Q profitKamada posts 4Q profit
finance.yahoo.com - February 8 at 8:49 AM
Kamada (KMDA) Rating Reiterated by HC WainwrightKamada (KMDA) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - February 8 at 7:50 AM
Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017
finance.yahoo.com - February 7 at 9:20 AM
Kamada (KMDA) Scheduled to Post Earnings on WednesdayKamada (KMDA) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 5 at 8:32 PM
Kamada (KMDA) Lowered to "Sell" at ValuEngineKamada (KMDA) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - February 5 at 12:28 AM
Kamada (KMDA) versus Chiasma (CHMA) Financial SurveyKamada (KMDA) versus Chiasma (CHMA) Financial Survey
www.americanbankingnews.com - February 2 at 3:38 PM
Kamada (KMDA) Receives New Coverage from Analysts at Chardan CapitalKamada (KMDA) Receives New Coverage from Analysts at Chardan Capital
www.americanbankingnews.com - February 2 at 2:33 PM
Kamada Ltd (KMDA) Receives Consensus Rating of "Hold" from AnalystsKamada Ltd (KMDA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 2 at 9:48 AM
Kamada to Announce Fiscal Year 2017 Financial Results and Host Conference Call on February 7Kamada to Announce Fiscal Year 2017 Financial Results and Host Conference Call on February 7
finance.yahoo.com - February 2 at 9:17 AM
Zacks: Kamada Ltd (KMDA) Given $8.50 Consensus Target Price by BrokeragesZacks: Kamada Ltd (KMDA) Given $8.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - January 17 at 12:04 PM
Analyzing ChemoCentryx (CCXI) & Kamada (KMDA)Analyzing ChemoCentryx (CCXI) & Kamada (KMDA)
www.americanbankingnews.com - January 15 at 11:16 PM
Contrasting Kamada (KMDA) and Biogen (BIIB)Contrasting Kamada (KMDA) and Biogen (BIIB)
www.americanbankingnews.com - January 15 at 9:06 AM
Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant RejectionKamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
finance.yahoo.com - January 8 at 10:20 AM
Kamada (KMDA) Raised to "Hold" at ValuEngineKamada (KMDA) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - January 5 at 11:22 PM
Kamada (KMDA) & Cesca Therapeutics (KOOL) Critical AnalysisKamada (KMDA) & Cesca Therapeutics (KOOL) Critical Analysis
www.americanbankingnews.com - January 5 at 5:34 PM
Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host DiseaseKamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease
finance.yahoo.com - January 4 at 10:06 AM
 Kamada Ltd (KMDA) Given Consensus Recommendation of "Strong Buy" by Brokerages Kamada Ltd (KMDA) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 31 at 1:28 PM
ETFs with exposure to Kamada Ltd. : December 28, 2017ETFs with exposure to Kamada Ltd. : December 28, 2017
finance.yahoo.com - December 28 at 4:42 PM
 Kamada Ltd (KMDA) Given $8.50 Average Target Price by Brokerages Kamada Ltd (KMDA) Given $8.50 Average Target Price by Brokerages
www.americanbankingnews.com - December 22 at 5:23 PM
Comparing Kamada (KMDA) & Opiant Pharmaceuticals (OPNT)Comparing Kamada (KMDA) & Opiant Pharmaceuticals (OPNT)
www.americanbankingnews.com - December 17 at 1:28 PM
ETFs with exposure to Kamada Ltd. : December 12, 2017ETFs with exposure to Kamada Ltd. : December 12, 2017
finance.yahoo.com - December 12 at 5:02 PM
ETFs with exposure to Kamada Ltd. : December 1, 2017ETFs with exposure to Kamada Ltd. : December 1, 2017
finance.yahoo.com - December 1 at 5:29 PM
Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 10:47 AM
 Kamada Ltd. (KMDA) Given Average Rating of "Strong Buy" by Analysts Kamada Ltd. (KMDA) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 27 at 11:26 AM
Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies InfectionKamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection
finance.yahoo.com - November 22 at 1:38 AM
 Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages Kamada Ltd. (KMDA) Given $8.50 Average Target Price by Brokerages
www.americanbankingnews.com - November 21 at 5:50 PM
Critical Review: Argos Therapeutics (ARGS) vs. Kamada (KMDA)Critical Review: Argos Therapeutics (ARGS) vs. Kamada (KMDA)
www.americanbankingnews.com - November 21 at 5:12 AM
Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin DeficiencyKamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency
finance.yahoo.com - November 21 at 2:07 AM
Kamada Ltd. (KMDA) Downgraded by Zacks Investment Research to Strong SellKamada Ltd. (KMDA) Downgraded by Zacks Investment Research to Strong Sell
www.americanbankingnews.com - November 19 at 8:40 AM
 Kamada Ltd. (KMDA) Receives Average Recommendation of "Strong Buy" from Analysts Kamada Ltd. (KMDA) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 17 at 8:40 AM
Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017
finance.yahoo.com - November 13 at 11:29 AM
Oversold Conditions For Kamada (KMDA)Oversold Conditions For Kamada (KMDA)
www.thestreet.com - November 11 at 3:16 PM
Kamada Announces Nomination of Three New Members to its Board of DirectorsKamada Announces Nomination of Three New Members to its Board of Directors
finance.yahoo.com - November 11 at 3:16 PM
Kamada Ltd. (KMDA) Scheduled to Post Earnings on MondayKamada Ltd. (KMDA) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 9 at 2:01 PM
Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13
finance.yahoo.com - November 8 at 12:33 PM
Kamadas AAT fails to show significant treatment effect in type 1 diabetics in mid-stage study; shares down 4% premarketKamada's AAT fails to show significant treatment effect in type 1 diabetics in mid-stage study; shares down 4% premarket
seekingalpha.com - November 2 at 4:24 AM
Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes PatientsKamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients
finance.yahoo.com - November 2 at 4:24 AM
Zacks: Brokerages Expect Kamada Ltd. (KMDA) Will Announce Quarterly Sales of $24.84 MillionZacks: Brokerages Expect Kamada Ltd. (KMDA) Will Announce Quarterly Sales of $24.84 Million
www.americanbankingnews.com - October 31 at 5:56 AM
Comparing Kamada (KMDA) & Its PeersComparing Kamada (KMDA) & Its Peers
www.americanbankingnews.com - October 30 at 11:24 PM
Contrasting Sinovac Biotech (SVA) and Kamada (KMDA)Contrasting Sinovac Biotech (SVA) and Kamada (KMDA)
www.americanbankingnews.com - October 30 at 7:40 PM
$0.01 Earnings Per Share Expected for Kamada Ltd. (KMDA) This Quarter$0.01 Earnings Per Share Expected for Kamada Ltd. (KMDA) This Quarter
www.americanbankingnews.com - October 30 at 12:56 AM
ETFs with exposure to Kamada Ltd. : October 25, 2017ETFs with exposure to Kamada Ltd. : October 25, 2017
finance.yahoo.com - October 26 at 4:31 PM

SEC Filings

Kamada (NASDAQ:KMDA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kamada (NASDAQ:KMDA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kamada (NASDAQ KMDA) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.